Long-term results of neoadjuvant treatment with M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for locally invasive transitional cell carcinoma of the urothelium

International Journal of Clinical Oncology

Volumn 4, Issue 1, 1999, Pages 32-35

  Miyake, Hideaki ^a   Gohji, Kazuo ^a   Hara, Isao ^a   Eto, Hiroshi ^a   Yamanaka, Kazuki ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Neoadjuvant M VAC; Prognostic factors; Urothelial cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032978590     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470050020     Document Type: Article

References (11)

1. Lerner SP, Skinner E, Skinner DG (1992) Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 19:713-723
2. Miyake H, Hara I, Fujisawa M, et al. (1996) Prognostic variables in patients with upper urinary tract cancers. Int J Clin Oncol 1:135-138
3. Trasher JB, Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957-967
4. Gohji K, Sugino M, Arakawa S, et al. (1990) Preoperative adjuvant therapy for urinary bladder cancer (in Japanese). Jap J Urol 81:1404-1411
5. Sternberg CN, Yagota A, Scher HI, et al. (1985) Preliminary results of M-VAC (methotrexate, vinblastin, doxorubicine and cisplatin) for transitional cell carcinoma of the urothelium (in Japanese). J Urol 133:403-407
6. The Japanese Urological Association, Japanese Pathological Society (1993) General rules for clinical and pathological studies on bladder cancer (in Japanese). Kanehara, Tokyo
7. The Japanese Urological Association, Japanese Pathological Society (1992) General rules for clinical and pathological studies on renal, pelvic and ureteral cancer (in Japanese). Kanehara, Tokyo
8. Srougi M, Simon SD (1994) Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer. J Urol 151:593-597
9. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr D, Bosl GJ, Scher HI (1994) Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 12:1394-1401
10. Splinter TAW, Scher HI, Denis L, et al., EEORTC-GU Group (1992) The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 147:606-608
11. Scher HI, Yagoda A, Herr HW, et al. (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139:470-474